A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of WS016 in Patients With Hyperkalemia
Latest Information Update: 03 Dec 2025
At a glance
- Drugs WS 016 (Primary)
- Indications Hyperkalaemia
- Focus Registrational; Therapeutic Use
- Sponsors Waterstone Pharmaceuticals
Most Recent Events
- 03 Dec 2025 New trial record